Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Sells $368,340.00 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Rating) EVP Tolga Tanguler sold 1,754 shares of the company’s stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $210.00, for a total transaction of $368,340.00. Following the sale, the executive vice president now directly owns 3,629 shares of the company’s stock, valued at approximately $762,090. The sale was disclosed in a filing with the SEC, which is available at this link.

Tolga Tanguler also recently made the following trade(s):

  • On Friday, August 5th, Tolga Tanguler sold 1,841 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $218.16, for a total transaction of $401,632.56.
  • On Tuesday, July 5th, Tolga Tanguler sold 1,754 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $150.00, for a total transaction of $263,100.00.

Alnylam Pharmaceuticals Stock Down 2.4 %

Alnylam Pharmaceuticals stock traded down $5.47 during mid-day trading on Friday, reaching $218.58. 1,356,539 shares of the company’s stock were exchanged, compared to its average volume of 889,480. The company has a market cap of $26.24 billion, a P/E ratio of -27.42 and a beta of 0.74. Alnylam Pharmaceuticals, Inc. has a twelve month low of $117.58 and a twelve month high of $226.00. The company has a quick ratio of 3.62, a current ratio of 3.76 and a debt-to-equity ratio of 3.85. The company has a fifty day moving average of $143.40 and a 200-day moving average of $147.42.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) last released its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.67). The business had revenue of $224.80 million for the quarter, compared to analyst estimates of $256.06 million. Alnylam Pharmaceuticals had a negative return on equity of 204.18% and a negative net margin of 110.91%. Alnylam Pharmaceuticals’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the company earned ($1.61) earnings per share. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.85 EPS for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Gateway Investment Advisers LLC increased its position in shares of Alnylam Pharmaceuticals by 474.4% in the 1st quarter. Gateway Investment Advisers LLC now owns 26,239 shares of the biopharmaceutical company’s stock valued at $4,285,000 after purchasing an additional 21,671 shares during the last quarter. Shell Asset Management Co. increased its position in shares of Alnylam Pharmaceuticals by 54.7% in the 4th quarter. Shell Asset Management Co. now owns 5,808 shares of the biopharmaceutical company’s stock valued at $985,000 after purchasing an additional 2,053 shares during the last quarter. Spire Wealth Management increased its position in shares of Alnylam Pharmaceuticals by 188.5% in the 1st quarter. Spire Wealth Management now owns 1,350 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 882 shares during the last quarter. DNB Asset Management AS increased its position in shares of Alnylam Pharmaceuticals by 9.6% in the 1st quarter. DNB Asset Management AS now owns 21,355 shares of the biopharmaceutical company’s stock valued at $3,487,000 after purchasing an additional 1,868 shares during the last quarter. Finally, Clearstead Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 3.7% in the 4th quarter. Clearstead Advisors LLC now owns 3,110 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 110 shares during the last quarter. 92.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on ALNY. William Blair began coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, June 7th. They set an “outperform” rating for the company. Needham & Company LLC increased their price target on shares of Alnylam Pharmaceuticals from $205.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday. Guggenheim cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, June 27th. Citigroup increased their price target on shares of Alnylam Pharmaceuticals from $206.00 to $280.00 in a research note on Thursday. Finally, Chardan Capital increased their price target on shares of Alnylam Pharmaceuticals from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday. Six analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $225.75.

About Alnylam Pharmaceuticals

(Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Further Reading

Insider Buying and Selling by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.